Human primary fibroblasts perform similarly to MSCs in assays used to evaluate MSC safety and potency.

摘要: Background Cellular therapeutic agents may benefit trauma patients by modulating the immune response to injury, and reducing inflammation vascular leakage. Administration of allogeneic mesenchymal stromal cells (MSCs) shows some in preclinical clinical trials, but less testing has been performed with other cell types. Human primary fibroblasts (FBs) were compared MSCs assays designed evaluate determine if these actually properties unique or whether related types perform similarly. Study design methods MSC-related surface marker expression, tissue factor, human leukocyte antigen-D evaluated flow cytometry, vitro adipogenic osteogenic differentiation potential determined. Procoagulant activity was determined thromboelastography. Two potency correlated immunomodulation utilized: mixed lymphocyte reaction indoleamine 2,3-dioxygenase enzyme assays. Results FBs similarly MSC characteristics potency. Although similar for MSC-positive did not show robust adipose expressed level markers expected on MSCs. Conclusions are very MSCs, at least currently used Preclinical required vivo. If inferior vivo, development new MSC-specific will be necessary relevant their benefits.